Our top pick for
PolyPid Ltd is a biotechnology business based in the US. PolyPid shares (PYPD) are listed on the NASDAQ and all prices are listed in US Dollars. PolyPid employs 65 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$8.64 - $19.45|
|50-day moving average||$11.40|
|200-day moving average||$11.16|
|Wall St. target price||$25.80|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.51|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$0|
|Return on assets TTM||-29.96%|
|Return on equity TTM||-71.11%|
|Market capitalisation||$199.6 million|
TTM: trailing 12 months
There are currently 30,571 PolyPid shares held short by investors – that's known as PolyPid's "short interest". This figure is 29.2% down from 43,151 last month.
There are a few different ways that this level of interest in shorting PolyPid shares can be evaluated.
PolyPid's "short interest ratio" (SIR) is the quantity of PolyPid shares currently shorted divided by the average quantity of PolyPid shares traded daily (recently around 98616.129032258). PolyPid's SIR currently stands at 0.31. In other words for every 100,000 PolyPid shares traded daily on the market, roughly 310 shares are currently held short.
However PolyPid's short interest can also be evaluated against the total number of PolyPid shares, or, against the total number of tradable PolyPid shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PolyPid's short interest could be expressed as 0% of the outstanding shares (for every 100,000 PolyPid shares in existence, roughly 0 shares are currently held short) or 0.0033% of the tradable shares (for every 100,000 tradable PolyPid shares, roughly 3 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against PolyPid.
Find out more about how you can short PolyPid stock.
We're not expecting PolyPid to pay a dividend over the next 12 months.
PolyPid Ltd. develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in pivotal Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing PLEXONCO that is in preclinical studies for the treatment of cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petach Tikva, Israel. .
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.